Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion type Assertion NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_head.
- NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion description "[KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_provenance.
- NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion evidence source_evidence_literature NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_provenance.
- NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion SIO_000772 21271222 NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_provenance.
- NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion wasDerivedFrom befree-2016 NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_provenance.
- NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_assertion wasGeneratedBy ECO_0000203 NP868140.RArh_mz9X19KhH8FyEc2ZAvLC6rOFFHypGEqIlPv2Rx4o130_provenance.